All News

Methamphetamine deaths among American Indian and Native Alaskan men and women significantly increased between 1992 and 2019.

Your weekly roundup of the latest news from Drug Topics®.

A Kaiser Family Foundation analysis found the 10 drugs accounted for more than half of the increase in gross Part D spending from 2018 to 2021.

The news comes almost 2 weeks after Cyltezo’s entrance into the US biosimilars market as the first commercially available and FDA-approved interchangeable adalimumab biosimilar.

The approval of norgestrel (Opill) is expected to help reduce barriers to access by allowing people to obtain the medication without needing to see a health care provider.

Join industry experts on Saturday, June 15, to completely transform and revolutionize how you approach front- and back-end solutions within your pharmacy.

The company will also add Sandoz’s unbranded version of adalimumab to its National Preferred Formulary.

A recent study shows decreased use of multiple types of contraception among patients struggling with OUD.

Researchers concluded that older patients with stable MS can stop taking disease-modifying therapy because risk of relapse is so small.

The increase is expected to be somewhat offset by the impact of biosimilars coming to market and more care being provided in outpatient settings.

What's on the agenda for FTP in the upcoming month?

Odevixibat can now be used to treat cholestatic pruritus in young patients with Alagille syndrome (ALGS).

A study presented at Digestive Disease Week 2023 compared the effectiveness of different approaches to prevent complications in individuals with the common disease.

Delayed prophylaxis start and intermediate dose intensity of factor VIII prevents bleeds, but at a cost of more joint damage and possibly a lower QOL.

Your weekly roundup of the latest news from Drug Topics®.

What stood out on Sunday and Monday at the 2023 ASHP Summer Meetings in Baltimore?

Your weekly roundup of the latest news from Drug Topics®.

Advisers with the FDA endorse a monoclonal antibody treatment for RSV in children, AstraZeneca and Quell sign a $2 billion agreement, and HSS hopes to strengthen the pediatric workforce.

The newly approved at-home test was effective in trials, correctly identifying 98.7% of negative and 92.9% of positive samples for individuals with symptoms of upper respiratory infection.

Which masks (if any) serve as the best protection against wildfire smoke, and what do experts say about home appliances like air conditioners?

A survey shows cancer centers are struggling, Google expands its generative AI into health care, and the WHO announces enhanced collaboration with the Global Fund.

The median annual cost for new oncology medicines launched in 2022 was $260,000, up from $63,534 10 years ago, an IQVIA report finds.

Cue Health gets FDA’s first de novo approval for at-home COVID-19 test, Novavax says its new vaccine will fight new variants and HHS creates new cert standards for peer support workers.

Existing evidence-evaluation frameworks are not sufficiently targeted toward the specific factors relevant to digital health products, they argue.